Literature DB >> 23761563

Combination of Steven-Johnson syndrome and neuroleptic malignant syndrome following carbamazepine therapy: a rare occurrence.

Bhawna Sharma1, Raghavendra Bakki Sannegowda, Pankaj Gandhi, Parul Dubey, Ashok Panagariya.   

Abstract

Stevens-Johnson syndrome (SJS) is a severe, episodic, acute mucocutaneous reaction that is most often elicited by drugs and occasionally by infections. The drugs commonly implicated as the cause of SJS are anticonvulsants, sulfonamides, non-steroidal anti-inflammatory drugs and antibiotics. Carbamazepine (CBZ) has been commonly implicated in SJS. Neuroleptic malignant syndrome (NMS) is a rare, life-threatening but potentially treatable condition. Among the neuroleptics, haloperidol (parenteral) is implicated as a most common drug for NMS. Though rare, association of NMS with CBZ and association of NMS with toxic epidermal necrolysis (TEN) in a single patient after administration of neuroleptics has been reported in the literature before. However, a combination of NMS and SJS in a single patient after administration of CBZ has not been reported so far. We present a patient with seizure who developed SJS and NMS following administration of CBZ.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23761563      PMCID: PMC3702838          DOI: 10.1136/bcr-2013-008908

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  23 in total

Review 1.  Neuroleptic malignant syndrome.

Authors:  P Adnet; P Lestavel; R Krivosic-Horber
Journal:  Br J Anaesth       Date:  2000-07       Impact factor: 9.166

Review 2.  Neuroleptic malignant syndrome: a neuroimmunologic hypothesis.

Authors:  Rebecca E Anglin; Patricia I Rosebush; Michael F Mazurek
Journal:  CMAJ       Date:  2010-08-09       Impact factor: 8.262

3.  Atypical case of neuroleptic malignant syndrome caused by olanzapine and carbamazepine.

Authors:  Benjamin Kp Woo; Gabriela V Obrocea
Journal:  Psychiatry (Edgmont)       Date:  2005-12

4.  Simultaneous occurrence of toxic epidermal necrolysis and neuroleptic malignant syndrome.

Authors:  K Muhammed; P Raman
Journal:  Indian J Dermatol Venereol Leprol       Date:  2005 Jul-Aug       Impact factor: 2.545

5.  Carbamazepine and forme fruste neuroleptic malignant syndrome.

Authors:  T Dalkin; A S Lee
Journal:  Br J Psychiatry       Date:  1990-09       Impact factor: 9.319

Review 6.  Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome.

Authors:  Pierre-Dominique Ghislain; Jean-Claude Roujeau
Journal:  Dermatol Online J       Date:  2002-06

7.  Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade?

Authors:  V W Henderson; G F Wooten
Journal:  Neurology       Date:  1981-02       Impact factor: 9.910

8.  Management of neuroleptic malignant syndrome--a series of eight cases.

Authors:  T Kurien; K K Rajeev; O C Abraham; S Archana; A M Cherian
Journal:  J Assoc Physicians India       Date:  1993-02

9.  The neuroleptic malignant syndrome: a report of 14 cases from North India.

Authors:  A Panagariya; B Sharma; R Singh; V Agarwal; A Dev
Journal:  Neurol India       Date:  2007 Apr-Jun       Impact factor: 2.117

10.  Effect of iron chelators on dopamine D2 receptors.

Authors:  D Ben-Shachar; J P Finberg; M B Youdim
Journal:  J Neurochem       Date:  1985-10       Impact factor: 5.372

View more
  2 in total

1.  Neuroleptic Malignant Syndrome Associated with Lithium Toxicity.

Authors:  Vaibhav Patil; Rishab Gupta; Rohit Verma; Yatan Pal Singh Balhara
Journal:  Oman Med J       Date:  2016-07

Review 2.  Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective.

Authors:  Lurdes Tse; Alasdair M Barr; Vanessa Scarapicchia; Fidel Vila-Rodriguez
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.